The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. ##STR00001##

The present disclosure describes novel PKC-? activators chosen from halogenated esters of unsaturated fatty acids derivatives thereof, including halogenated esters of both polyunsaturated and monunsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. ##STR00001##

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. ##STR00001##

There is described a suspension concentrate, containing the following components: (a) at least one agrochemical active substance which is solid at room temperature; (b) at least one oil, selected from the group consisting of mineral oils and/or liquid paraffins; and (c) at least one emulsifier; and (d) at least one triglyceride.

There is described a suspension concentrate, containing the following components: (a) at least one agrochemical active substance which is solid at room temperature; (b) at least one oil, selected from the group consisting of mineral oils and/or liquid paraffins; and (c) at least one emulsifier; and (d) at least one triglyceride.

There is described a suspension concentrate, containing the following components: (a) at least one agrochemical active substance which is solid at room temperature; (b) at least one oil, selected from the group consisting of mineral oils and/or liquid paraffins; and (c) at least one emulsifier; and (d) at least one triglyceride.

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides.

##STR00001##

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides.

##STR00001##

Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca.sup.2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.